Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caraco Pharmaceutical Laboratories has been granted final approval from the FDA to market a generic version of Boehringer Ingelheim's anti-inflammatory Mobic.
Subscribe to our email newsletter
Caraco’s Meloxicam Tablets is the generic equivalent of Boehringer Ingelheim’s Mobic, a nonsteroidal anti-inflammatory drug, (NSAID) indicated for the relief of the signs and symptoms of osteoarthritis. Caraco has two strengths available, 7.5mg and 15mg tablets.
The generics firm said it plans to launch the product, which will boost Caraco’s existing NSAID line, immediately.
“We are pleased to gain this approval and have another product to market, adding value to our portfolio of products we market in the US,” commented Daniel Movens, Caraco’s CEO. “This approval brings our total marketed product selection to 22 different products represented by 47 strengths.”